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The present investigation is based on an in vitro incompatibility study between valsartan and hydrochlorothiazide by 
spectroscopic and reverse-phase high-pressure liquid chromatography (RP-HPLC) methods. The method has been developed 
and validated by ultraviolet (UV) spectroscopic method using methanol and water (1:4) as the solvent. The RP-HPLC study has 
been carried out using acetonitrile, methanol and 50 Mm phosphate buffer (20:50:30 %) adjusted to pH 3 with orthophosphoric 
acid. The methods show linearity at the concentration range of 1-5 μg/ml with correlation coefficient 0.9994 for valsartan and  
0.9978 for hydrochlorothiazide in the concentration range of 1-5 μg/ml. Both the methods have shown a percentage relative 
standard deviation values less than 2. The in vitro incompatibility study has been carried out by UV-spectroscopic and 
RP-HPLC methods. The results of the study show that there is a change in the concentration level of both drugs in combination. 
The structure of the interacting compound has been determined by spectral analysis using IR, 1H NMR and LC-MS study. The 
spectral analysis confirms the formation of the new complex between valsartan and hydrochlorothiazide. The results obtained 
from the LC-MS study also correlate the reason behind an increase in the concentration of valsartan and decreases the 
concentration of hydrochlorothiazide during recovery study by spectroscopic and RP-HPLC method. 
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In recent years the Indian union health ministry banned 
most of the combinational drugs due to their adverse 
effects and drug-drug interactions. These interactions 
lead to change in the chemical property of the dosage 
form which is known as chemical incompatibility1. 
Valsartan is chemically N-pentanonyl-N-[2'-(l H-
tetrazole-5-yl) biphenyl-4-yl methyl]-L-valine. This is 
mainly used as anti-hypertensive2. Valsartan is an 
angiotensin II receptor blocker. Activation of 
angiotensin II includes constricting blood vessels and 
activating aldosterone to reduce blood pressure3. 
Hydrochlorothiazide is chemically 6-chloro-3, 4-
dihydro-2H-1, 2, 4benzothiadiazine-7-sulphonamide 
1,1-dioxide. This is mainly used as a diuretic. 
Hydrochlorothiazide belongs to the thiazide class of 
diuretics. It reduces blood volume by acting on the 
kidneys to reduce sodium (Na+) reabsorption in the 
distal convoluted tubule4. The combination drug 
mainly used to treat high blood pressure. Lowering 
high blood pressure helps prevent strokes, heart attacks 
and kidney problems5. The literature review reveals 
that valsartan and hydrochlorothiazide were previously 
estimated by spectrophotometry6-8, RP-HPLC9, 10, 
HPTLC11, UPLC12 and some hyphenated techniques 
like HPLC-MS/MS also used for estimation of 
valsartan in plasma13. The present study describes there 
is a chemical incompatibility between valsartan and 
hydrochlorothiazide. It leads to the formation of a new 
chemical molecule by the synthesis of these two drugs. 
These types of studies were previously explained by 
using UV spectroscopy, HPLC14, IR and NMR15. 
Materials and Methods 
Original standards of valsartan hydrochlorothiazide 
were provided by the Caplin point laboratories 
limited, Pondicherry. Formulations of valsartan 
(Valzaar-40 mg), hydrochlorothiazide (Cipla-12.5 
mg) and valsartan and hydrochlorothiazide 
combination dosage form (Valembic) were purchased 
from local markets. HPLC grade methanol, 
acetonitrile, and water were purchased from Merck, 
Mumbai, India. Potassium dihydrogen orthophosphate 
& orthophosphoric acid was purchased from 
Research-Lab fine chem industries. 
Instruments 
The instrument used for the present study was a 
double beam UV spectrophotometer (ELICO SL 244) 
using 1.00 cm quartz cuvette. The weighing process 
was carried out in SHIMADZU AUX 220, RP-HPLC 
(Make: Cyber labs; Software: LC-100 with C8 




column and UV detector), ultrasonicator (Citizen), 
FTIR (Perkin Elmer), and NMR (Bruker Avance-II 
400 MHz), HRLCMS (Make: Agilent Technologies, 
USA Model: 1290 Infinity UHPLC System, Nano 
HPLC with Chipcube, 6550 I Funnel Q-TOFs). 
 
Preparation of standard stock solution 
Accurately weighed 10 mg of valsartan and 
hydrochlorothiazide were transferred separately to  
10 ml of volumetric flasks followed by the addition of 
2 ml methanol. The mixture was sonicated for  
10 min and finally, volume was made up with water 
(1000 μg /ml). From the above stock solutions,  
1-5 μg / ml concentration of valsartan and 
hydrochlorothiazide were prepared.  
 
Preparation of test stock solution 
Individually 10 tablets of valsartan and 
hydrochlorothiazide weighed, their mean weight was 
calculated and triturated to make a fine powder. Then 
weight equivalent to 10 mg of valsartan and 
hydrochlorothiazide were taken in 2 different 10 ml 
volumetric flasks, made up the volume up to 10 ml 
with methanol and water (1:4) which gave 1000 μg/ 
ml (stock solution). The mixture was sonicated for  
30 min, above stock solution was filtered and diluted 
to prepare 1-5 μg /ml concentration of valsartan and 
hydrochlorothiazide. 
 
Selection of wavelength 
The prepared 10μg /ml concentration of valsartan 
and hydrochlorothiazide were scanned in a UV visible 
spectrophotometer in the range of 200-400 nm. 
 
UV- spectroscopic method validation 
The proposed method was extensively validated in 
terms of specificity, linearity, accuracy, precision, 
robustness, ruggedness, limits of detection (LOD) and 
quantification (LOQ) as per ICH guidelines16. 
 
In-vitro drug interaction studies by the spectroscopic method 
Percentage recovery study using solvent system (methanol and 
water 1:4) 
10 μg /ml solutions of valsartan and 
hydrochlorothiazide were prepared individually. From 
the above solutions 0.5 ml of valsartan and 0.5 ml of 
hydrochlorothiazide was taken in a 10 ml volumetric 
flask, 2 ml of methanol was added and made up the 
volume with water and mixed thoroughly and the 
contents of the volumetric flask transferred into round 
bottom flask and heated it for 120 min at 37 ºC then 
the sample was withdrawn for every 30 min. The 
samples were scanned in UV at respective λmax against 
reagent blank.  
Percentage recovery study using phosphate buffer (pH: 6.8) 
10 μg /ml solutions of valsartan and 
hydrochlorothiazide individually using phosphate 
buffer (pH: 6.8) were prepared. From the above 
solutions 0.5 ml of valsartan and 0.5 ml of 
hydrochlorothiazide were taken in a 10 ml volumetric 
flask. 5 ml of phosphate buffer (pH: 6.8) was added to 
mix the contents and made up the volume with 
phosphate buffer (pH: 6.8). After transfer, the 
contents of the volumetric flask into the flask, it was 
heated for 120 min at 37 ºC then the sample was 
withdrawn for every 30 min. The samples were 




For RP-HPLC method17 the mobile phase was 
acetonitrile: methanol: 50 mM phosphate buffer 
adjusted to pH-3 with orthophosphoric acid 
(20:50:30) and Flowrosil C18 (250 x 4.6 mm, 5 µm) 
column was used. The flow rate, run time, injection 
volume and wavelength were set to be 1 ml/min,  
5 min, 20 µL and 265 nm, respectively. 
 
Preparation of standard stock solution 
Accurately 10 mg of valsartan and 
hydrochlorothiazide were weighed individually and 
transferred separately to 10 ml of volumetric flasks.  
5 ml of mobile phase was added the solutions and 
sonicated for 10 min and then made up to 10 ml with 
mobile phase (1000 μg/ml). Then above stock 
solutions were diluted to prepare 10 μg/ml solutions 
of valsartan and hydrochlorothiazide separately. 
These were used for further analysis.  
 
Preparation of test stock solution 
10 tablets of valsartan and hydrochlorothiazide 
fixed-dose combination tablets were taken and 
weighed and they were transferred into the motor and 
triturated to make a fine powder. From this weight 
equivalent to 10 mg of valsartan and 
hydrochlorothiazide was taken in a 10 ml volumetric 
flask. The volume was made up to 10 ml with the 
mobile phase. This gave 1000 μg/ml (stock solution). 
The above stock solution was filtered and the filtered 
solution was diluted to prepare 10 μg/ml solution of 
valsartan and hydrochlorothiazide. 
 
In vitro drug interaction studies by RP-HPLC method 
Percentage recovery study using RP-HPLC solvent system 
100 μg/ml solutions of valsartan and 
hydrochlorothiazide were prepared individually using 




the mobile phase. From the above solutions, 0.75 ml 
of valsartan and 0.75 ml of hydrochlorothiazide were 
taken in a 10 ml volumetric flask, 5 ml of mobile 
phase was added and the contents were mixed and 
made up to volume with the mobile phase. The 
content of the volumetric flask was transfer into the 
RBF flask and heated for 120 min at 37 ºC then the 
sample was withdrawn after every 30 min. Then the 
solution was filtered and injected into the HPLC 
system. The % recovery of each drug was calculated. 
 
Synthesis of the mixture of valsartan and hydrochlorothiazide 
The equimolar ratio of valsartan and 
hydrochlorothiazide was taken in 50 ml of round 
bottom flask then add 10 ml of methanol and refluxed 
for 3 h. After that the mixture was cooled, filtered and 
dried by a solvent evaporation method. The dried 
synthetic product was delivered for spectral analysis 
(IR, NMR, and LC-MS) to determine the structure of 
the formed compound. 
 
Results and Discussion 
The absorption spectra for valsartan and 
hydrochlorothiazide are shown in Fig. 1. The 
maximum wavelength (λmax) for valsartan and 
hydrochlorothiazide was found to be 231 and 271 nm, 
respectively. This new cheapest UV method was 
developed using methanol and water (1:4) and 
validated according to ICH guidelines. It is evident 
from Table 1 and 2 that both the drugs show linearity 
at the concentration range of 1-5 μg/ml. Fig. 2 shows 
the calibration curves of valsartan and 
hydrochlorothiazide in UV-spectroscopic method. 
The correlation coefficient is found to be 0.9994 for 
valsartan and 0.9978 for hydrochlorothiazide. 
The assay results of valsartan in tablet dosage form 
at 2 µg/ml and hydrochlorothiazide at 1 µg/ml are 
given in Table 3 and 4, respectively. Both the 
methods were shown %RSD values less than 2. The 
percentage recovery study was also carried out 
individually and it was found to be 98% for valsartan 
and 90% for hydrochlorothiazide as shown in Table 5. 
The RP-HPLC study was carried out using 
acetonitrile, methanol, and 50 Mm phosphate buffer 
(20:50:30 %) adjusted to pH-3 with orthophosphoric 
acid by the previously reported method developed by 
Jothieswari D (2011). The plots are given in Fig. 3. 
The proposed method also exhibited a correlation 
coefficient of 0.999 and the method is well accepted. 
The optimized chromatogram of valsartan and 
hydrochlorothiazide are given in Fig. 4.  
The in vitro drug interaction study was carried out 
using the developed method for UV-spectroscopy and  
 
Fig. 1 — Absorption spectra of (a) valsartan and (b)
hydrochlorothiazide solution (Solvent- methanol: water (1:4)).  
Table 1 — Linearity study of valsartan at 1-5 µg /ml 







1 1 0.0887 0.0016 1.75472 
2 2 0.1857 0.00081 0.54475 
3 3 0.2753 0.0009 0.34679 
4 4 0.3696 0.00305 0.97452 
5 5 0.4525 0.00668 1.60284 
 
 









1 1 0.13032 0.000162 1.2443 
2 2 0.21053 0.00237 1.1246 
3 3 0.34073 0.05714 1.6770 
4 4 0.45087 0.00557 1.2348 




Fig. 2 — Calibration curves of valsartan and hydrochlorothiazide 
in UV-spectroscopic method.  




RP-HPLC. The study was carried out by a percentage 
recovery study using a combination of both drugs. In 
UV-spectroscopic method methanol and water (1:4) 
(Table 6) and phosphate buffer (pH 6.8) (Table 7) 
were used. For both, the study equal ratio of each 
drug was taken with the designed concentration of  
1 μg/ml. The mixture was warmed at body 
temperature at 37 ºC in a thermostat water bath and 
the absorbance was recorded at 30 min interval for 2 
h. Fig. 5 shows the calibration curves of valsartan and 
hydrochlorothiazide in RP-HPLC method. During 2 h 
of recovery study, it was found that there is a change 
in the concentration level of both the drugs. The 
concentration of valsartan was increased whereas that 
of hydrochlorothiazide was decreased. 
 
Similarly, the in vitro interaction study was carried 
out using the RP-HPLC method using solvent system 
acetonitrile, methanol and 50 mM phosphate buffer 
(20:50:30%) adjusted to pH 3 with orthophosphoric 
acid (Table 8). It was found that the concentration of 
valsartan was increased and hydrochlorothiazide was 
decreased continuously during 2 h of study. Fig. 6 
Table 3 — Assay result of valsartan in tablet dosage  
form at 2 µg/ml 




1 %  
RSD 
0.144 0.00077 0.541% 
 
 
Table 4 — Results of the assay for hydrochlorothiazide at 1 µg/ml 





0.07861 0.00012 0.14769% 
 
 
Table 5 — Summary of validation parameters for the  
proposed methods  






231 nm 271 nm 
2 
Beer’s Law limit 
(μg/ml) 
1-5 μg/ml 1-5 μg/ml 
3 Slope 0.009463 0.100141 






















Limit of detection 
(LOD) 




0.163 μg/ml 0.161 μg/ml 
 
 
Fig. 3 — In-vitro interaction studies by percentage recovery of 
valsartan and hydrochlorothiazide in methanol and water (1:4) and 




Fig. 4 — Optimized chromatogram of valsartan and 
hydrochlorothiazide.  
 
Table 6 — In vitro incompatibility study by percentage recovery 
in methanol and water (1:4) using UV spectroscopy 
Time 
Valsartan Hydrochlorothiazide 
At 231 nm %Recovery At 271 nm %Recovery 
Initial 0.1899 103 0.0908 46 
30 min 0.1956 106 0.0835 43 
60 min 0.1963 107 0.0739 39 
90 min 0.2171 118 0.0721 38 
120 min 0.2241 122 0.071 37 
 
 
Table 7 — In vitro incompatibility study by percentage recovery 
in phosphate buffer using UV spectroscopy 
Time 
Valsartan Hydrochlorothiazide 
At 231 nm % Recovery At 271 nm % Recovery 
Initial 0.1647 92 0.1038 53 
30 min 0.1561 87 0.1062 54 
60 min 0.1521 85 0.1041 62 
90 min 0.1490 83 0.1250 63 
120 min 0.1450 81 0.1354 67 




shows the plots for in vitro interaction studies by 
percentage recovery of valsartan and hydro–
chlorothiazide in RP-HPLC using solvent system. 
From the recovery study by UV-Spectroscopy  
and RP-HPLC, it was found that there was a  
change in the concentration of both valsartan and 
hydrochlorothiazide. For further verification of result 
complex of valsartan and hydrochlorothiazide was 
synthesized using methanol as a solvent. The structure 
of the complex was characterized by IR, 1H NMR and 
LC-MS study. 
The IR study was carried out by using the KBr 
pellet technique. Fig. 7 shows the FTIR spectra of 
hydrochlorothiazide, valsartan and complex of both 
drugs. The assignment of IR bands was made by 
comparing the spectra of 2 drugs and the complex 
formed due to interacting drugs. The valsartan gives a 
characteristic peak at 1730.35 cm-1 indicates the 
presence of the carbonyl group which is carboxylic in  
nature. The presence of a characteristic peak at 1598 
cm-1 (N-H secondary amine) and 1163.43 cm-1 
(SO2NH2) indicates the presence of hydro–
chlorothiazide. The missing of the characteristic peak 
at 1730 cm-1 for carboxylic acid and 1163 cm-1 for 
SO2NH2 indicates formation of the new complex from 
participating drug. 
Further 1H NMR study was carried out using 
DMSO d6 and the plots are shown in Fig. 8. The 
carboxylic acid of valsartan gives a characteristic 
singlet peak at δ value 12.01 and hydrochlorothiazide 
has given a singlet peak at 2.5 for SO2NH2 group. But 
in the case of the complex interacting drug a new 
singlet peak appeared at δ value 2.01 indicate the 
formation of the new complex of interacting drug. 
The result obtained from the IR and 1HNMR study 
was further confirmed by the LC-MS study of 
synthesized compounds. The results indicated the 
presence of these components in a mixture with 
retention time value 4.64, 11.32 and 12.56 min  
(Fig. 9) having molecular mass (m/z) value 295.95 for 
hydrochlorothiazide, 434.22 for valsartan and  
448.23 for the complex compound (Fig. 10).  
From FTIR and 1H NMR study it was found that 
due to chemical incompatibility between valsartan 
and  hydrochlorothiazide  the  formation   of  unstable  
 
 
Fig. 6 — In-vitro Interaction Studies by percentage recovery of




Fig. 7 — FTIR spectra of hydrochlorothiazide, valsartan and
complex of both drugs.  
 
Fig. 5 — Calibration curves of valsartan and hydrochlorothiazide 
in RP-HPLC method. 
 
Table 8 — In vitro incompatibility study by percentage recovery 
using RP-HPLC method 
S. N. Time  Retention time Area % of the drug 
present 
VAL HTCZ VAL HTCZ VAL HTCZ 
1 Initial 2.32 2.72 29407 46444 100 100 
2 30 2.32 2.72 30212 45212 102.7 97.3 
3 60 2.32 2.72 31123 44201 105.8 95.1 
4 90 2.32 2.72 31840 43123 108.2 92.8 
5 120 2.32 2.72 32214 42101 109.5 90.6 











Fig. 9 — LC-MS chromatogram of Hydrochlorothiazide, valsartan and complex of both drugs. 
 
 
compound named as (S)-N-((2'-(2H-tetrazole-5-yl)-
[1,1'-biphenyl] -4 -yl) methyl) -N- (1-((6-chloro-1,1-
dioxido-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-
sulfonamido)oxy)-3-methyl-1-oxobutan-2-yl) pentan-
amide having molecular formula C30H31ClN8O7S22
• 
(Exact Mass: 714.14) was taken place. During LC-MS 
study it was found there was the presence of a  
new compound with molecular mass 448.23 at  
12.56 min. The compound can be named  
as (S)-((2-(N-((2'-(2H-tetrazole-5-yl)-[1,1'-biphenyl]-
4-yl) methyl) pentanamido)-3-methylbutanoyl) oxy) 
nitride in which valsartan moiety is prominent. Due to 
which the concentration of valsartan  
was increased during the in vitro recovery study.  
The result obtained from the LC-MS study  
(Table 9) also correlates with increased  
concentration of valsartan and decreased the 
concentration of hydrochlorothiazide during  
recovery study by spectroscopic and RP-HPLC 
method.  







Fig. 10 — ESI mass spectra by LC-MS for hydrochlorothiazide, valsartan and complex of both drugs in negative mode. 
 










Type of  
Peak 
Structure of  
compounds 







2 11.32 5557616 109643441 434.22 
 
Valsartan 
3 12.56 3480291 34878286 448.23 
 
Unknown fragmented compound 
 






Based on spectral and RP-HPLC analysis, it is 
confirmed that there is the formation of an interacting 
complex between valsartan and hydrochlorothiazide. 
This indicates there is in vitro chemical 
incompatibility take place between valsartan and 
hydrochlorothiazide which may produce synergistic 
or antagonist effect on concurrent administration or in 
the combined dosage form. 
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